High frequencies of CYP2C19 mutations and poor metabolism of proguanil in Vanuatu [2]

Lancet

Volumn 349, Issue 9056, 1997, Pages 921-922

  Kaneko, Akira ^a   Kaneko, Osamu ^b   Taleo, George ^b   Björkman, Anders ^b   Kobayakawa, Takatoshi ^b  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; PROGUANIL;

DRUG METABOLISM; GENE MUTATION; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALARIA; PRIORITY JOURNAL; VANUATU;

EID: 0030975288     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)62696-7     Document Type: Article

References (5)

1. Radloff PD, Philipps J, Nkeyi M, Hutchinson D, Kremsner PG. Atovaquone and proguanil for Plasmodium falciparum malaria. Lancet 1996; 347: 1511-14.
2. Ward SA, Helsby NA, Skjelbo E, Brosen K, Gram LF, Breckenridge AM. The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism - a panel study. Br J Clin Pharmacol 1991; 31: 689-92.
3. Bertilsson L. Geographical/interracial differences in polymorphic drug oxidation. Clin Pharmacokinet 1995; 29: 192-209.
4. de Morais SMF, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 1994; 46: 594-98.
5. Katayama K. A scenario on prehistoric Mongoloid dispersals into the South Pacific, with special reference to hypothetic proto-oceanic connection. Man Culture Oceania 1990; 6: 151-59.